Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca and its R&D arm, MedImmune, disclosed that its investigational anti-CD19 monoclonal
antibody, MEDI-551, was given Orphan Drug Status by the FDA. (marketexclusive.com)
GlaxoSmithKline s CEO A dre Witty retires as chief executive in March 2017, after a career at the
company spanning more than 30 years and a tumultuous near-decade as its chief. (wsj.com)
Novartis’ heart-failure pill Entresto hits hurdles ith do tors’ pres riptio . The drug had so far $
million in sales, while $126 million were expected by industry analysts. (wsj.com)
Novo Nordisk's hemophilia drug Novoeight infringed claims of a Baxter International Inc. patent, a
U.S. International Trade Commission court ruled. (bna.com)
Roche announced that the FDA has accepted the company's Biologics License Application (BLA) and
granted Priority Review for atezolizumab. (fiercebiotech.com)
Sanofi could pay privately held DiCE Molecules as much as $2.3 billion under a partnership deal that
aims to find new oral medicines to replace injections for certain diseases. (reuters.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 3
2016-03-20
Amgen AstraZeneca BioMarin Daiichi Sankyo Healthcare Eli Lilly Fisher & Paykel
GlaxoSmithKline Johnson & Johnson Kyowa Hakko Kirin Novartis Novo Nordisk Pfizer
SPOTLIGHT
COMPANY NEWS
Amgen s t o pate ts li ked to the o pa y’s re e tly appro ed holesterol-lowering drug have
been declared valid by a jury. (wsj.com)
BioMarin is going to yield news this month on its drug in phase III in phenylketonuria (PKU). The drug
is a promising candidate to treat an as yet incurable condition. (marketexclusive.com)
Eli Lilly changed the scientific goal of a closely at hed Phase Alzhei er’s trial of its sola ezu a
drug i people ith ild Alzhei er’s de e tia. It ill o o ly ie og itio . (wsj.com)
Johnson & Johnson and its DePuy unit were ordered to pay about $500 million to five plaintiffs who
said they were injured by Pinnacle metal-on-metal hip implants. (reuters.com)
Pfizer's Xalkori has won a new use in patients with rare variation of lung cancer. The FDA says Xalkori
capsules are now approved for patients with the ROS-1 gene mutation. (usnews.com)
Fisher & Paykel Healthcare was the 2015 Supreme Winner of ExportNZ's annual awards, generating
99 percent of its revenue from exports, while forecasting operating revenue of $800m. (stuff.co.nz)
Daiichi Sankyo Healthcare found out in a survey that elderly people retaining their natural teeth
prefer toothpastes preventing gum disease, alveolar pyorrhea and bad breath. (japantimes.co.jp)
Kyowa Hakko Kirin will start the operations of drug product manufacturing facility from March 2016
in China. The project involves an investment of some 1 billion yen. (thepharmaletter.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
94%
96%
98%
100%
102%
2016-03-14 2016-03-15 2016-03-16 2016-03-17 2016-03-18
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
Taking a closer look at the regional development of the biggest listed health care companies, there
was an overall weekly decline of -3.4% on a global level, further increasing the loss of -16.1% on a
yearly basis. Worst performance this week showed the North American region with -3.8%, followed
by Europe with -2.94%. Both regions reach double digit negative development on a yearly basis.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 3
2016-03-20
Actelion Coloplast Gerresheimer Hikma Pharmaceuticals
Lonza Group Morphosys Orpea Roche Sanofi Stada
SPOTLIGHT
FINANCIAL MARKET NEWS
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
689.56 -2.94% -18.53% 719.14 686.64 879.13 654.95
STOXX® North America 600
Health Care
776.32 -3.82% -16.80% 811.48 758.75 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
414.56 -1.74% -0.24% 427.22 412.33 446.92 349.32
STOXX® Global 1800
Health Care
684.53 -3.43% -16.14% 713.99 675.86 842.76 647.94
The strongest performer from Europe in the weekly performance ranking is Stada with an increase of
+6.7% while its one year performance reaches +11.9%. Second is Hikma Pharmaceuticals with a value
gain of +6.3% on a weekly basis though it shows a negative development of -25.2% on a yearly basis.
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Stada 34.28 +6.69% +11.94% 34.28 32.21 37.37 28.07
Hikma Pharmaceuticals 23.31 +6.27% -25.21% 23.88 20.88 34.56 20.88
Morphosys 41.61 +4.36% -39.25% 43.35 39.82 76.96 33.82
Lonza Group 159.50 +3.03% +25.35% 148.11 141.71 151.00 111.63
Gerresheimer 68.27 +2.75% +31.43% 69.23 66.80 76.43 48.73
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Actelion 119.88 -6.29% +9.58% 129.29 120.10 142.12 105.57
Roche 214.63 -4.79% -15.52% 228.74 212.51 279.90 212.50
Orpea 72.26 -4.55% +19.86% 76.60 70.81 76.72 58.21
Coloplast 65.48 -4.51% -7.90% 70.20 65.07 78.50 55.69
Sanofi 70.73 -4.36% -23.44% 75.36 70.84 101.00 66.50
Regarding this week’s low performers from Europe, the worst development experienced Actelion
with a decrease of -6.3%, although its one year change still shows +9.6%. In second place is Roche
with a loss of -4.8% on a weekly basis, further deteriorating its one year decline of -15.5%.